

Kim-Heang Ly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6468790/publications.pdf>

Version: 2024-02-01

28
papers

849
citations

471371

17
h-index

477173

29
g-index

32
all docs

32
docs citations

32
times ranked

917
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathogenesis of giant cell arteritis: More than just an inflammatory condition?. <i>Autoimmunity Reviews</i> , 2010, 9, 635-645.	2.5	110
2	Interleukin-1 blockade in refractory giant cell arteritis. <i>Joint Bone Spine</i> , 2014, 81, 76-78.	0.8	73
3	Cerebral abscesses in hereditary haemorrhagic telangiectasia: A clinical and microbiological evaluation. <i>Clinical Neurology and Neurosurgery</i> , 2012, 114, 235-240.	0.6	66
4	Involvement and prognosis value of CD8 + T cells in giant cell arteritis. <i>Journal of Autoimmunity</i> , 2016, 72, 73-83.	3.0	56
5	Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients. <i>Journal of Rheumatology</i> , 2016, 43, 1547-1552.	1.0	56
6	Giant-cell arteritis: concordance study between aortic CT angiography and FDG-PET/CT in detection of large-vessel involvement. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2274-2279.	3.3	54
7	Risk Factors for Permanent Visual Loss in Biopsy-proven Giant Cell Arteritis: A Study of 339 Patients. <i>Journal of Rheumatology</i> , 2016, 43, 1393-1399.	1.0	51
8	Recovery of Adrenal Function after Long-Term Glucocorticoid Therapy for Giant Cell Arteritis: A Cohort Study. <i>PLoS ONE</i> , 2013, 8, e68713.	1.1	41
9	Different patterns and specific outcomes of large-vessel involvements in giant cell arteritis. <i>Journal of Autoimmunity</i> , 2019, 103, 102283.	3.0	36
10	Tocilizumab as an add-on therapy to glucocorticoids during the first 36 months of treatment of Giant cell arteritis: A prospective study. <i>European Journal of Internal Medicine</i> , 2018, 57, 96-104.	1.0	29
11	Steroid-sparing effect and toxicity of dapsone treatment in giant cell arteritis. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT /Overlock</i>	0.4	28
12	Molecular analysis of vascular smooth muscle cells from patients with giant cell arteritis: Targeting endothelin-1 receptor to control proliferation. <i>Autoimmunity Reviews</i> , 2017, 16, 398-406.	2.5	28
13	Giant-Cell Arteritis: Do We Treat Patients with Large-Vessel Involvement Differently?. <i>American Journal of Medicine</i> , 2017, 130, 992-995.	0.6	28
14	Proteomic analysis of vascular smooth muscle cells in physiological condition and in pulmonary arterial hypertension: Toward contractile versus synthetic phenotypes. <i>Proteomics</i> , 2016, 16, 2637-2649.	1.3	25
15	Contribution of antiferritin antibodies to diagnosis of giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1269-1270.	0.5	23
16	Steroid-sparing effect of anakinra in giant-cell arteritis: a case series with clinical, biological and iconographic long-term assessments. <i>Rheumatology</i> , 2021, 61, 400-406.	0.9	20
17	Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 127.	1.2	19
18	Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis. <i>Clinical and Translational Immunology</i> , 2021, 10, e1332.	1.7	18

#	ARTICLE	IF	CITATIONS
19	Development of Giant Cell Arteritis after Treating Polymyalgia or Peripheral Arthritis: A Retrospective Case-control Study. <i>Journal of Rheumatology</i> , 2018, 45, 678-685.	1.0	15
20	Features and prognosis of giant cell arteritis in patients over 85 years of age: A case-control study. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 288-295.	1.6	11
21	Diagnostic Value of 18F-FDG PET/CT vs. Chest-Abdomen-Pelvis CT Scan in Management of Patients with Fever of Unknown Origin, Inflammation of Unknown Origin or Episodic Fever of Unknown Origin: A Comparative Multicentre Prospective Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 386.	1.0	11
22	Cornea verticillata and acroparesthesia efficiently discriminate clusters of severity in Fabry disease. <i>PLoS ONE</i> , 2020, 15, e0233460.	1.1	9
23	Giant cell arteritis presenting as isolated inflammatory response and/or fever of unknown origin: a case-control study. <i>Clinical Rheumatology</i> , 2018, 37, 3405-3410.	1.0	8
24	Risk profiling for a refractory course of giant cell arteritis: The importance of age and body weight. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1252-1261.	1.6	8
25	Venous thrombosis in patients with giant cell arteritis: Features and outcomes in a cohort study. <i>Joint Bone Spine</i> , 2017, 84, 323-326.	0.8	6
26	An uncommon case of dyspnea with unilateral laryngeal paralysis in acromegaly. <i>Auris Nasus Larynx</i> , 2016, 43, 105-107.	0.5	5
27	Vascular Presentation and Outcomes of Patients With Giant Cell Arteritis and Isolated Symptomatic Limb Involvement. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 248-254.	0.5	3
28	Blocage de l'interleukine-1 dans la maladie de Horton réfractaire. <i>Revue Du Rhumatisme (Edition) Tj ETQq0 0,0 rgBT /Overlock 10</i>	0.0	0